COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS
Objectives: Bruton tyrosine kinase inhibitors (BTKi) are associated with an increased risk of bleeding events. Pirtobrutinib, a non-covalent (reversible) BTKi FDA approved for treatment of R/R MCL after 2 lines of therapy including a BTKi, demonstrated efficacy and tolerability across multiple B-cel...
Main Authors: | N Lamanna, CS Tam, W Jurczak, A Kontos, H Konig, AS Ruppert, DE Tsai, AAS Scheliga |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-10-01
|
Series: | Hematology, Transfusion and Cell Therapy |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137923005357 |
Similar Items
-
P1088: COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS
by: Nicole Lamanna, et al.
Published: (2023-08-01) -
STRATEGY TO MINIMIZE THE BLEEDING RISKS IN PATIENTS WITH ATRIAL FIBRILLATION WHO RECEIVE COMBINED ANTITHROMBOTIC THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION
by: D. A. Zateishchikov
Published: (2018-05-01) -
Pharmacokinetic and Pharmacogenetic Predictors of Major Bleeding Events in Patients with an Acute Coronary Syndrome and Atrial Fibrillation Receiving Combined Antithrombotic Therapy
by: Olga Baturina, et al.
Published: (2023-09-01) -
Health-related quality of life after adverse bleeding events associated with antithrombotic drug therapy – A systematic review
by: Lodewijk C.S. Res, et al.
Published: (2019-01-01) -
A quality‐of‐life questionnaire for heavy menstrual bleeding in Thai women receiving oral antithrombotics: Assessment of the translated Menstrual Bleeding Questionnaire
by: Tinaram Rodpetch, et al.
Published: (2021-10-01)